Showing results (2221-2230 of 2,570) with videos related to

Sort By:
Pageof 257
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Targeting wild type NTRK decreases brain metastases of lung cancers non-driven by NTRK fusionsMaria J Contreras-Zárate, Jenny A Jaramillo-Gómez, R Alejandro Marquez-Ortiz, et al.
Diabetologia|March 22, 2022
XBP1 maintains beta cell identity, represses beta-to-alpha cell transdifferentiation and protects against diabetic beta cell failure during metabolic stress in miceKailun Lee, Jeng Yie Chan, Cassandra Liang, et al.
Journal of General Internal Medicine|April 20, 2005
A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosisShuvayu S Sen, Vincent P Rives, Osvaldo D Messina, et al.
Scientific Reports|March 17, 2018
On-target action of anti-tropomyosin drugs regulates glucose metabolismAnthony J Kee, Jayshan Chagan, Jeng Yie Chan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.
Military Medicine|September 23, 2025
A Novel, Reverse-Phase-Shifting, Thermoreversible Foaming Hydrogel Containing Antibiotics for the Treatment of Traumatic Tissue Injuries in a Swine ModelRoss I Donaldson, Aslam A Akhtar, Arghavan Farzadi, et al.
AIDS (London, England)|October 7, 2022
Gut microbiota and plasma metabolites associated with bone mineral density in women with or at risk of HIV infectionZhendong Mei, Michael T Yin, Anjali Sharma, et al.
Pageof 257